Regeneron Pharmaceuticals Stock Price on November 9, 2024
| REGN Stock | USD 773.00 5.50 0.71% |
Below is the normalized historical share price chart for Regeneron Pharmaceuticals extending back to April 02, 1991. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Regeneron Pharmaceuticals stands at 773.00, as last reported on the 11th of December 2024, with the highest price reaching 781.31 and the lowest price hitting 766.87 during the day.
If you're considering investing in Regeneron Stock, it is important to understand the factors that can impact its price. Regeneron Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.36, which implies the firm had a -0.36% return per unit of risk over the last 3 months. Regeneron Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Regeneron Pharmaceuticals' Variance of 3.02, risk adjusted performance of (0.23), and Coefficient Of Variation of (306.80) to confirm the risk estimate we provide.
At this time, Regeneron Pharmaceuticals' Total Stockholder Equity is very stable compared to the past year. As of the 11th of December 2024, Liabilities And Stockholders Equity is likely to grow to about 34.7 B, while Common Stock Shares Outstanding is likely to drop about 75.4 M. . At this time, Regeneron Pharmaceuticals' Price Fair Value is very stable compared to the past year. Regeneron Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 2nd of April 1991 | 200 Day MA 991.9597 | 50 Day MA 877.493 | Beta 0.142 |
Regeneron |
Sharpe Ratio = -0.36
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | REGN |
Estimated Market Risk
| 1.73 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.62 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.36 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Regeneron Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regeneron Pharmaceuticals by adding Regeneron Pharmaceuticals to a well-diversified portfolio.
Price Book 2.9528 | Enterprise Value Ebitda 14.4496 | Price Sales 6.2535 | Shares Float 103.1 M | Wall Street Target Price 1.1 K |
Related Headline
Puma Biotechnology Headline on 8th of November 2024
Puma Biotechnology Inc Q3 2024 Earnings Call Highlights Reve... by gurufocus.com
Total Revenue 80.5 million for Q3 2024.Product Revenue Net 56.1 million in Q3 2024, up from 44.4 million in Q2 2024 and 51.6 million in Q3 2023.Royalty R
Regeneron Pharmaceuticals Valuation on November 9, 2024
It is possible to determine the worth of Regeneron Pharmaceuticals on a given historical date. On November 9, 2024 Regeneron was worth 826.57 at the beginning of the trading date compared to the closed value of 828.42. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Regeneron Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Regeneron Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Regeneron Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Regeneron Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 817.88 | 832.53 | 814.05 | 824.48 | 774,080 | |
11/08/2024 | 826.57 | 830.73 | 822.80 | 828.42 | 563,540 |
| 824.00 | 834.42 | 820.45 | 825.68 | 638,740 |
| Backtest Regeneron Pharmaceuticals | | | Regeneron Pharmaceuticals History | | | Regeneron Pharmaceuticals Valuation | Previous | Next |
Regeneron Pharmaceuticals Trading Date Momentum on November 9, 2024
| On November 11 2024 Regeneron Pharmaceuticals was traded for 825.68 at the closing time. The top price for the day was 834.42 and the lowest listed price was 820.45 . The trading volume for the day was 638.7 K. The trading history from November 11, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 0.33% . The trading delta at closing time against the current closing price is 8.99% . |
Regeneron Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Regeneron Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Regeneron Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Regeneron financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Regeneron Pharmaceuticals Stock history
Regeneron Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Regeneron is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Regeneron Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Regeneron Pharmaceuticals stock prices may prove useful in developing a viable investing in Regeneron Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 113.7 M | 75.4 M | |
| Net Income Applicable To Common Shares | 5 B | 5.2 B |
Regeneron Pharmaceuticals Quarterly Net Working Capital |
|
Regeneron Pharmaceuticals Stock Technical Analysis
Regeneron Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Regeneron Pharmaceuticals Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Regeneron Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Regeneron Pharmaceuticals December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Regeneron Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Regeneron Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Regeneron Pharmaceuticals stock market strength indicators, traders can identify Regeneron Pharmaceuticals entry and exit signals to maximize returns
Regeneron Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Regeneron Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Regeneron Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Regeneron to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.23) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.85) | |||
| Treynor Ratio | (0.86) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.4 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.